ASN-90 is under clinical development by Asceneuron and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success ...
Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study ... Nov. 19, 2024 — A recently published study ...